Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J. Castillo(Miriam Hospital), Steven P. Treon(Dana-Farber Cancer Institute), Christopher J. Patterson(Dana-Farber Cancer Institute), Andrew R. Branagan(Massachusetts General Hospital), Amanda Kofides(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Noopur Raje(Massachusetts General Hospital), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Timothy P. White(Dana-Farber Cancer Institute), Andrew J. Yee(Harvard University), Catherine Flynn(Dana-Farber Cancer Institute), Elizabeth O’Donnell(Harvard University), Carly Leventoff(Dana-Farber Cancer Institute), Xia Liu(Shaanxi Research Association for Women and Family), Maria Luisa Guerrera(Harvard University), Manit Munshi(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Shayna Sarosiek(Harvard University), Kirsten Meid(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Lian Xu(Huazhong Agricultural University), Zachary R. Hunter(Shaanxi Research Association for Women and Family)
Cited by 82
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunopathology of Hyperinflammation in COVID-19
|American Journal Of Pathology|2020|526